{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:11:17Z","timestamp":1790295077995,"version":"4.1.0"},"reference-count":50,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["PCEFP3_181355"],"award-info":[{"award-number":["PCEFP3_181355"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011318","name":"Fondation Botnar","doi-asserted-by":"publisher","award":["REG\u201019\u2010008"],"award-info":[{"award-number":["REG\u201019\u2010008"]}],"id":[{"id":"10.13039\/501100011318","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>HIV programmes across many countries in Africa have recently transitioned people living with HIV from efavirenz (EFV)\u2010 to dolutegravir (DTG)\u2010containing antiretroviral therapy (ART). As both drugs are associated with neuropsychiatric adverse effects, this study assessed the mental health and HIV\/ART\u2010associated symptoms of people living with HIV before and after transition to DTG.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The prospective DO\u2010REAL cohort enrolled people starting DTG\u2010based ART in Lesotho from February to December 2020. For this analysis within DO\u2010REAL, we included adults changing from tenofovir disoproxil fumarate (TDF)\/lamivudine (3TC)\/EFV to TDF\/3TC\/DTG within first\u2010line therapy. At transition and 16\u2009weeks thereafter, participants completed the Patient Health Questionnaire\u20109 (PHQ\u20109; depression screening), the 12\u2010item Short\u2010Form Health Survey (SF\u201012; mental and physical health), and a modified HIV Symptom Index (mHSI; HIV\/ART\u2010related symptoms). We also assessed weight change. We used McNemar tests with Bonferroni corrections to assess binary outcomes.<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>: NCT04238767.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 1228 participants, 1131 completed follow\u2010up. Of these, 60.0% were female, the median age was 46\u2009years (interquartile range [IQR] 38\u201355), and the median time taking ART was 5.7\u2009years (IQR 3.5\u20138.9). No change was observed for weight or overall PHQ\u20109 or SF\u201012 outcomes. However, three mHSI items decreased at follow\u2010up: \u2018feeling sad\/down\/depressed\u2019 (bothered 6.0% vs. 3.3% of participants at least \u2018a little\u2019 before vs. after transition; adjusted<jats:italic>p<\/jats:italic>\u00a0=\u00a00.048); \u2018feeling nervous\/anxious\u2019 (7.4% vs. 3.4%; adjusted<jats:italic>p<\/jats:italic>\u00a0=\u00a00.0009); and \u2018nightmares, strange\/vivid dreams\u2019 (6.3% vs. 3.5%; adjusted<jats:italic>p<\/jats:italic>\u00a0=\u00a00.027). Individual PHQ\u20109 or SF\u201012 items also improved. Being symptom free across all measures increased from 5.1% to 11.4% (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>We observed no negative impacts and potential moderate improvements with DTG, providing further support for the rollout of DTG.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hiv.13352","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T07:23:31Z","timestamp":1655882611000},"page":"153-162","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Dolutegravir in real life: Self\u2010reported mental and physical health outcomes after transitioning from efavirenz\u2010 to dolutegravir\u2010based antiretroviral therapy in a prospective cohort study in Lesotho"],"prefix":"10.1111","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1874-6153","authenticated-orcid":false,"given":"Jennifer A.","family":"Brown","sequence":"first","affiliation":[{"name":"Swiss Tropical and Public Health Institute Basel Switzerland"},{"name":"Molecular Virology Group Department of Biomedicine Basel Switzerland"},{"name":"University of Basel Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bienvenu L.","family":"Nsakala","sequence":"additional","affiliation":[{"name":"SolidarMed Partnerships for Health Maseru Lesotho"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuena","family":"Mokhele","sequence":"additional","affiliation":[{"name":"SolidarMed Partnerships for Health Maseru Lesotho"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itumeleng","family":"Rakuoane","sequence":"additional","affiliation":[{"name":"SolidarMed Partnerships for Health Maseru Lesotho"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1314-4543","authenticated-orcid":false,"given":"Josephine","family":"Muhairwe","sequence":"additional","affiliation":[{"name":"SolidarMed Partnerships for Health Maseru Lesotho"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7075-9803","authenticated-orcid":false,"given":"Tracy R.","family":"Glass","sequence":"additional","affiliation":[{"name":"Swiss Tropical and Public Health Institute Basel Switzerland"},{"name":"University of Basel Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1716-993X","authenticated-orcid":false,"given":"Alain","family":"Amstutz","sequence":"additional","affiliation":[{"name":"Swiss Tropical and Public Health Institute Basel Switzerland"},{"name":"University of Basel Basel Switzerland"},{"name":"University Hospital Basel Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7303-9542","authenticated-orcid":false,"given":"Nadine","family":"Tschumi","sequence":"additional","affiliation":[{"name":"Swiss Tropical and Public Health Institute Basel Switzerland"},{"name":"University of Basel Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4091-4889","authenticated-orcid":false,"given":"Jennifer M.","family":"Belus","sequence":"additional","affiliation":[{"name":"Swiss Tropical and Public Health Institute Basel Switzerland"},{"name":"University of Basel Basel Switzerland"},{"name":"University of Maryland College Park Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4945-6511","authenticated-orcid":false,"given":"Thomas","family":"Klimkait","sequence":"additional","affiliation":[{"name":"Molecular Virology Group Department of Biomedicine Basel Switzerland"},{"name":"University of Basel Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3599-1791","authenticated-orcid":false,"given":"Niklaus D.","family":"Labhardt","sequence":"additional","affiliation":[{"name":"Swiss Tropical and Public Health Institute Basel Switzerland"},{"name":"University of Basel Basel Switzerland"},{"name":"University Hospital Basel Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,6,22]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz256"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1904340"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30238-1"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902824"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30241-1"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215541"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000790"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100573"},{"key":"e_1_2_12_10_1","unstructured":"UNAIDS.New high\u2010quality antiretroviral therapy to be launched in South Africa Kenya and over 90 low\u2010and middle\u2010income countries at reduced price [Internet].2017[cited 2021 Feb 5]. Available from:https:\/\/www.unaids.org\/en\/resources\/presscentre\/pressreleaseandstatementarchive\/2017\/september\/20170921_TLD"},{"key":"e_1_2_12_11_1","volume-title":"Interim Guidelines: Updated Recommendations on First\u2010Line and Second\u2010Line Antiretroviral Regimens and Post\u2010Exposure Prophylaxis and Recommendations on Early Infant Diagnosis of HIV. Supplement to the 2016 Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection [Internet]","author":"World Health Organization","year":"2018"},{"key":"e_1_2_12_12_1","unstructured":"Ministry of Health Government of Lesotho.Addendum to the national guidelines on the use of antiretroviral therapy for HIV prevention and treatment. Ministry of Health Government of Lesotho;2019."},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-016-0440-y"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv183"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.117.013706"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40506-019-00203-7"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001269"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.24875\/AIDSRev.19000023"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12468"},{"key":"e_1_2_12_20_1","unstructured":"Clinton Health Access Initiative.HIV Market Report [Internet].Clinton Health Access Initiative;2020. Report No.: 11. Available from:https:\/\/3cdmh310dov3470e6x160esb-wpengine.netdna-ssl.com\/wp-content\/uploads\/2020\/09\/2020-CHAI-HIV-Market-Report.pdf"},{"key":"e_1_2_12_21_1","unstructured":"Dolutegravir in Real Life in Lesotho (DO\u2010REAL) [Internet].2020. [cited 2020 Mar 9]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04238767"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13189"},{"key":"e_1_2_12_23_1","unstructured":"UNAIDS Data 2021 [Internet].Geneva Switzerland: UNAIDS;2021[cited 2022 Jan 31]. Available from:https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/JC3032_AIDS_Data_book_2021_En.pdf"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2001.016009606.x"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(01)00449-8"},{"key":"e_1_2_12_26_1","volume-title":"SF\u201012: how to Score the SF\u201012 Physical & Mental Health Summary Scales (Second Edition)","author":"Ware JE","year":"1995"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0203797"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-019-2339-5"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100621"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002224"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2014.06.003"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2016.03.006"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2013.764385"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-020-00987-3"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-017-0708-7"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/heapol\/czr039"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2017.1417970"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.16.1.18867"},{"issue":"3","key":"e_1_2_12_39_1","first-page":"361","article-title":"Incomplete adherence among treatment\u2010experienced adults on antiretroviral therapy in Tanzania","volume":"29","author":"Denison JA","year":"2015","journal-title":"Uganda and Zambia AIDS"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.13173"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0062611"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0147309"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2017.1290209"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220337"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000616"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/nur.21806"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-019-0257-8"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2018.10.005"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0181960"},{"issue":"2","key":"e_1_2_12_50_1","doi-asserted-by":"crossref","first-page":"e25705","DOI":"10.1002\/jia2.25705","article-title":"Prevalence and factors associated with common mental disorders in young people living with HIV in sub\u2010Saharan Africa: a systematic review","volume":"24","author":"Too EK","year":"2021","journal-title":"J Int AIDS Soc"},{"key":"e_1_2_12_51_1","unstructured":"The DTG\u2010SWITCH Study: Longitudinal Analysis of Virologic Failure and Drug Resistance at and After Switching to Dolutegravir\u2010based First\u2010line ART [Internet].2020[cited 2021 Jul 12]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04612452"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.13352","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hiv.13352","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.13352","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T14:48:55Z","timestamp":1700750935000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.13352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,22]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1111\/hiv.13352"],"URL":"https:\/\/doi.org\/10.1111\/hiv.13352","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,22]]},"assertion":[{"value":"2022-04-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}